SCHEMBL21787709

SCHEMBL21787709

CC1CN(C)C[C@H]1c1ccccc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM1A O60341 3/20 0.47
KDM1B Q8NB78 1/20 0.47
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CYP3A4 P08684 1/20 0.39
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
DRD2 P14416 1/20 0.38
GABRA1 P14867 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
DRD1 P21728 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18022528 1.00 MEN1 (0.51) MEN1KMT2AKDM1AKDM1BHTR2C
SCHEMBL21547405 0.83 MEN1 (0.44) MEN1KMT2AHTR2CHTR2BSLC6A2
SCHEMBL17113820 0.81 HTR2C (0.43) KDM1AHTR2CHTR2BMAOAMAOB
SCHEMBL17086752 0.81 HTR2C (0.43) KDM1AHTR2CHTR2BMAOAMAOB
SCHEMBL17086753 0.81 HTR2C (0.43) KDM1AHTR2CHTR2BMAOAMAOB
SCHEMBL14908010 0.81 KDM1A (0.59) MEN1KMT2AKDM1AKDM1BHTR2C
SCHEMBL16110654 0.81 KDM1A (0.59) MEN1KMT2AKDM1AKDM1BHTR2C
SCHEMBL17460933 0.79 BRD4 (0.48) HTR2CHTR2BSLC6A2SLC6A4SLC6A3
SCHEMBL19223236 0.79 MEN1 (0.49) MEN1KMT2AKDM1AKDM1BHTR2C
SCHEMBL17864278 0.79 HTR2A (0.44) MEN1KMT2AHTR2CHTR2BMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020046966-A1 TREATMENT OF ADENOCARCINOMAS WITH MAPK PATHWAY INHIBITORS KURA ONCOLOGY, INC. (US) 2020-03-05 WO disclosed